Ibio Inc (IBIO)

$1.93 +0.09 (4.89%)
Market Cap 87.44M
Revenue (ttm) 400,000.00
Net Income (ttm) -18.38M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin -4,595.00%
Debt to Equity Ratio 0.00
Volume 854,793
Avg Vol 951,024
Day's Range N/A - N/A
Shares Out 49.68M
Stochastic %K 51%
Beta 1.26
Analysts Strong Sell
Price Target $5.46

Company Profile

iBio, Inc., a preclinical stage biotechnology company, engages in the development of artificial intelligence (AI) antibodies solutions for cardiometabolic and obesity space. The company's technology platforms include EngageTx that provides improved CD3 T-cell engager antibody panel; ShieldTx, an antibody masking technology that enables the creation of conditionally activated antibodies; StableHu, an AI antibody-optimizing technology; and AI epitope steering technology that guides antibodies agai...

Industry: Biotechnology
Sector: Healthcare
Phone: 979 446 0027
Website: ibioinc.com
Address:
11750 Sorrento Valley Road, Suite 200, San Diego, United States
Retail_Lives_Matter
Retail_Lives_Matter Jun. 4 at 6:59 PM
$IBIO
0 · Reply
Retail_Lives_Matter
Retail_Lives_Matter Jun. 4 at 3:03 AM
$IBIO so beautiful Marty….and yet your shareholders continue to eat 💩
2 · Reply
skitime
skitime Jun. 3 at 5:47 PM
$IBIO but what about the Ebola vaccine 🤷‍♂️
0 · Reply
focafoca99
focafoca99 Jun. 2 at 8:10 PM
$IBIO heads to the Jefferies Global Healthcare Conference on June 4 and the Leerink Partners Therapeutics Forum in July. https://www.rapidticker.com/news/ibio-ibio-to-participate-in-upcoming-0ec7fa
0 · Reply
Rower5oh
Rower5oh Jun. 2 at 8:10 PM
$IBIO “iBio is a clinical company now!!!” Price drops 7% 🤦‍♂️
1 · Reply
diagio
diagio Jun. 2 at 7:31 PM
$HUBC This idiot disappeared for 2 years when he lost his as on $IBIO he will disappear for another 2 years again. Look at his post history. 🤣
0 · Reply
Retail_Lives_Matter
Retail_Lives_Matter Jun. 2 at 6:40 PM
$IBIO remember when that POFS Tom said becoming a clinical stage company would be a major inflection point? I hope he stubs his toe really hard today.
1 · Reply
Bevobrack
Bevobrack Jun. 2 at 6:35 PM
$IBIO most news like this would warrant some interest and an uptick but not our IBIO lol. Wow. 😑
0 · Reply
Magglo
Magglo Jun. 2 at 6:27 PM
$IBIO ????
1 · Reply
Retail_Lives_Matter
Retail_Lives_Matter Jun. 2 at 12:22 PM
$IBIO
0 · Reply
Latest News on IBIO
iBio, Inc. Transcript: Jefferies Global Healthcare Conference 2026

Jun 4, 2026, 11:40 AM EDT - 6 hours ago

iBio, Inc. Transcript: Jefferies Global Healthcare Conference 2026

iBio to Participate in Upcoming Healthcare Investor Conferences

Jun 2, 2026, 4:01 PM EDT - 2 days ago

iBio to Participate in Upcoming Healthcare Investor Conferences

iBio doses first participant in IBIO-600 trial

2026-06-02T11:44:33.000Z - 2 days ago

iBio doses first participant in IBIO-600 trial

iBio Becomes a Clinical-Stage Company with First Participant Dosed in Phase 1 Clinical Trial of IBIO-600 in Adults with Obesity

Jun 2, 2026, 7:00 AM EDT - 2 days ago

iBio Becomes a Clinical-Stage Company with First Participant Dosed in Phase 1 Clinical Trial of IBIO-600 in Adults with Obesity

iBio, Inc. Slides: Corporate presentation

May 15, 2026, 7:00 AM EDT - 20 days ago

iBio, Inc. Slides: Corporate presentation

iBio reports Q3 EPS (7c), consensus (6c)

2026-05-12T21:36:01.000Z - 23 days ago

iBio reports Q3 EPS (7c), consensus (6c)

iBio Reports Q3 Fiscal Year 2026 Financial Results and Provides Corporate Update

May 12, 2026, 4:05 PM EDT - 23 days ago

iBio Reports Q3 Fiscal Year 2026 Financial Results and Provides Corporate Update

iBio, Inc. Earnings release: Q3 2026

May 12, 2026, 4:00 PM EDT - 23 days ago

iBio, Inc. Earnings release: Q3 2026

iBio, Inc. Quarterly report: Q3 2026

May 12, 2026, 4:00 PM EDT - 23 days ago

iBio, Inc. Quarterly report: Q3 2026

iBio, Inc. Transcript: Status update

Apr 8, 2026, 2:00 PM EDT - 2 months ago

iBio, Inc. Transcript: Status update

iBio receives regulatory clearance to initiate IBIO-600 trial in Australia

2026-04-08T11:12:57.000Z - 2 months ago

iBio receives regulatory clearance to initiate IBIO-600 trial in Australia

iBio Received Regulatory Clearance to Initiate Its Phase 1 Clinical Trial of IBIO-600 in Australia

Apr 8, 2026, 7:00 AM EDT - 2 months ago

iBio Received Regulatory Clearance to Initiate Its Phase 1 Clinical Trial of IBIO-600 in Australia

Biotech Alert: Searches spiking for these stocks today

2026-03-30T16:21:02.000Z - 2 months ago

Biotech Alert: Searches spiking for these stocks today

ACOG

iBio, Inc. Transcript: Study update

Mar 17, 2026, 4:00 PM EDT - 2 months ago

iBio, Inc. Transcript: Study update

iBio to provide update on cardiopulmonary program

2026-03-16T20:40:52.000Z - 2 months ago

iBio to provide update on cardiopulmonary program

iBio to Provide an Update on Cardiopulmonary Program Targeting Pulmonary Hypertension Associated with Heart Failure with Preserved Ejection Fraction (PH-HFpEF)

Mar 16, 2026, 4:30 PM EDT - 2 months ago

iBio to Provide an Update on Cardiopulmonary Program Targeting Pulmonary Hypertension Associated with Heart Failure with Preserved Ejection Fraction (PH-HFpEF)

iBio, Inc. Transcript: Leerink Global Healthcare Conference 2026

Mar 9, 2026, 4:20 PM EDT - 3 months ago

iBio, Inc. Transcript: Leerink Global Healthcare Conference 2026

iBio announces new preclinical data from study evaluating IBIO-610

2026-03-09T11:10:09.000Z - 3 months ago

iBio announces new preclinical data from study evaluating IBIO-610

iBio Reports Preclinical Body Composition Data from Obese Non-Human Primates Treated with IBIO-610, a Potential First-in-Class Treatment for Fat-Selective Weight Loss

Mar 9, 2026, 7:00 AM EDT - 3 months ago

iBio Reports Preclinical Body Composition Data from Obese Non-Human Primates Treated with IBIO-610, a Potential First-in-Class Treatment for Fat-Selective Weight Loss

iBio, Inc. Slides: Corporate presentation

Mar 9, 2026, 7:00 AM EDT - 3 months ago

iBio, Inc. Slides: Corporate presentation

iBio initiated with a Buy at JonesResearch

2026-03-02T21:34:02.000Z - 3 months ago

iBio initiated with a Buy at JonesResearch

iBio files $200M mixed securities shelf

2026-02-27T21:36:51.000Z - 3 months ago

iBio files $200M mixed securities shelf

Biotech Alert: Searches spiking for these stocks today

2026-02-27T16:00:56.000Z - 3 months ago

Biotech Alert: Searches spiking for these stocks today

iBio, Inc. Registration statement: Registration Filing

Feb 27, 2026, 7:00 AM EST - 3 months ago

iBio, Inc. Registration statement: Registration Filing

iBio, Inc. Transcript: Oppenheimer 36th Annual Healthcare Life Sciences Conference

Feb 26, 2026, 2:00 PM EST - 3 months ago

iBio, Inc. Transcript: Oppenheimer 36th Annual Healthcare Life Sciences Conference

iBio to Participate in Upcoming Investor Conferences

Feb 24, 2026, 7:00 AM EST - 3 months ago

iBio to Participate in Upcoming Investor Conferences

iBio reports Q2 EPS (9c), consensus (6c)

2026-02-10T21:13:10.000Z - 4 months ago

iBio reports Q2 EPS (9c), consensus (6c)

iBio Reports Q2 Fiscal Year 2026 Financial Results and Provides Corporate Update

Feb 10, 2026, 4:05 PM EST - 4 months ago

iBio Reports Q2 Fiscal Year 2026 Financial Results and Provides Corporate Update

iBio, Inc. Quarterly report: Q2 2026

Feb 10, 2026, 4:00 PM EST - 4 months ago

iBio, Inc. Quarterly report: Q2 2026

iBio, Inc. Earnings release: Q2 2026

Feb 10, 2026, 4:00 PM EST - 4 months ago

iBio, Inc. Earnings release: Q2 2026

iBio, Inc. Registration statement: Registration Filing

Jan 30, 2026, 7:00 AM EST - 4 months ago

iBio, Inc. Registration statement: Registration Filing

iBio prices 11.06M shares at $2.35 in private placement

2026-01-09T12:13:56.000Z - 5 months ago

iBio prices 11.06M shares at $2.35 in private placement

iBio Announces $26 Million Private Placement

Jan 9, 2026, 7:00 AM EST - 5 months ago

iBio Announces $26 Million Private Placement

Biotech Alert: Searches spiking for these stocks today

2026-01-08T17:16:04.000Z - 5 months ago

Biotech Alert: Searches spiking for these stocks today

iBio initiated with an Outperform at LifeSci Capital

2025-12-18T14:06:19.000Z - 6 months ago

iBio initiated with an Outperform at LifeSci Capital

ARWR WVE

iBio initiated with an Outperform at LifeSci Capital

2025-12-18T13:41:09.000Z - 6 months ago

iBio initiated with an Outperform at LifeSci Capital

Biotech Alert: Searches spiking for these stocks today

2025-12-11T16:45:34.000Z - 6 months ago

Biotech Alert: Searches spiking for these stocks today

CAMP

Biotech Alert: Searches spiking for these stocks today

2025-12-10T15:25:54.000Z - 6 months ago

Biotech Alert: Searches spiking for these stocks today

Biotech Alert: Searches spiking for these stocks today

2025-12-09T16:35:29.000Z - 6 months ago

Biotech Alert: Searches spiking for these stocks today

iBio, Inc. Transcript: Evercore ISI 8th Annual HealthCONx Conference

Dec 4, 2025, 8:45 AM EST - 6 months ago

iBio, Inc. Transcript: Evercore ISI 8th Annual HealthCONx Conference

iBio to Participate in the 8th Annual Evercore Healthcare Conference

Nov 24, 2025, 4:15 PM EST - 6 months ago

iBio to Participate in the 8th Annual Evercore Healthcare Conference

iBio, Inc. Slides: Corporate presentation

Nov 17, 2025, 7:00 AM EST - 7 months ago

iBio, Inc. Slides: Corporate presentation

iBio Reports Q1 Fiscal Year 2026 Financial Results and Provides Corporate Update

Nov 12, 2025, 4:01 PM EST - 7 months ago

iBio Reports Q1 Fiscal Year 2026 Financial Results and Provides Corporate Update

iBio, Inc. Earnings release: Q1 2026

Nov 12, 2025, 4:00 PM EST - 7 months ago

iBio, Inc. Earnings release: Q1 2026

iBio, Inc. Quarterly report: Q1 2026

Nov 12, 2025, 4:00 PM EST - 7 months ago

iBio, Inc. Quarterly report: Q1 2026

iBio, Inc. Transcript: Guggenheim Securities 2nd Annual Healthcare Innovation Conference

Nov 10, 2025, 8:30 AM EST - 7 months ago

iBio, Inc. Transcript: Guggenheim Securities 2nd Annual Healthcare Innovation Conference

iBio Unveils New Non-Human Primate Data on IBIO-610, an Activin E Antibody with Strong Therapeutic Potential for Fat-Selective Weight-Loss and Weight Maintenance

Oct 30, 2025, 7:00 AM EDT - 7 months ago

iBio Unveils New Non-Human Primate Data on IBIO-610, an Activin E Antibody with Strong Therapeutic Potential for Fat-Selective Weight-Loss and Weight Maintenance

iBio to Participate in the Guggenheim 2nd Annual Healthcare Innovation Conference

Oct 23, 2025, 7:00 AM EDT - 8 months ago

iBio to Participate in the Guggenheim 2nd Annual Healthcare Innovation Conference

iBio to Present New Preclinical Data on Its Activin E Antibody at Two Upcoming Scientific Conferences, ObesityWeek® and PEGS Europe 2025

Oct 21, 2025, 7:00 AM EDT - 8 months ago

iBio to Present New Preclinical Data on Its Activin E Antibody at Two Upcoming Scientific Conferences, ObesityWeek® and PEGS Europe 2025

iBio, Inc. Proxy statement: Proxy Filing

Oct 6, 2025, 8:00 AM EDT - 8 months ago

iBio, Inc. Proxy statement: Proxy Filing

iBio, Inc. Slides: Corporate Presentation

Sep 16, 2025, 7:00 AM EDT - 9 months ago

iBio, Inc. Slides: Corporate Presentation

iBio, Inc. Annual report: Q4 2025

Sep 5, 2025, 9:00 AM EDT - 9 months ago

iBio, Inc. Annual report: Q4 2025

iBio, Inc. Earnings release: Q4 2025

Sep 5, 2025, 9:00 AM EDT - 9 months ago

iBio, Inc. Earnings release: Q4 2025

iBio Reports Fiscal Year 2025 Financial Results and Provides Corporate Update

Sep 5, 2025, 7:30 AM EDT - 9 months ago

iBio Reports Fiscal Year 2025 Financial Results and Provides Corporate Update

iBio Announces Closing of $50 Million Public Offering

Aug 25, 2025, 7:00 AM EDT - 10 months ago

iBio Announces Closing of $50 Million Public Offering

iBio Announces Pricing of $50 Million Public Offering

Aug 19, 2025, 8:01 AM EDT - 10 months ago

iBio Announces Pricing of $50 Million Public Offering

iBio Announces Proposed Public Offering

Aug 18, 2025, 4:01 PM EDT - 10 months ago

iBio Announces Proposed Public Offering

iBio, Inc. Transcript: Study Update

Jun 24, 2025, 8:30 AM EDT - 1 year ago

iBio, Inc. Transcript: Study Update

iBio, Inc. Press release: Study Update

Jun 24, 2025, 8:30 AM EDT - 1 year ago

iBio, Inc. Press release: Study Update

iBio, Inc. Slides: Study Update

Jun 24, 2025, 8:30 AM EDT - 1 year ago

iBio, Inc. Slides: Study Update

iBio and AstralBio Unveil Obesity Program with Novel Amylin Agonist Antibody Demonstrating Promising In Vivo Results

Jun 24, 2025, 7:00 AM EDT - 1 year ago

iBio and AstralBio Unveil Obesity Program with Novel Amylin Agonist Antibody Demonstrating Promising In Vivo Results

iBio Presents Next-Generation Obesity and Cardiometabolic Pipeline Candidates on June 24 Conference Call

Jun 23, 2025, 4:15 PM EDT - 1 year ago

iBio Presents Next-Generation Obesity and Cardiometabolic Pipeline Candidates on June 24 Conference Call

iBio Initiates Non-Human Primate Study of First-in-Class Activin E Antibody Following Positive Preclinical Data Demonstrating Prevention in Weight Regain After GLP-1 Treatment

Jun 16, 2025, 7:00 AM EDT - 1 year ago

iBio Initiates Non-Human Primate Study of First-in-Class Activin E Antibody Following Positive Preclinical Data Demonstrating Prevention in Weight Regain After GLP-1 Treatment

iBio, Inc. Registration statement: Registration Filing

Jun 13, 2025, 8:00 AM EDT - 1 year ago

iBio, Inc. Registration statement: Registration Filing

iBio's First-in-Class Activin E Antibody Achieves >26% Fat Reduction Without Muscle Loss and Shows Synergy with GLP-1s in Preclinical Model

May 5, 2025, 8:00 AM EDT - 1 year ago

iBio's First-in-Class Activin E Antibody Achieves >26% Fat Reduction Without Muscle Loss and Shows Synergy with GLP-1s in Preclinical Model

iBio Reports Fiscal Third Quarter 2025 Financial Results

May 2, 2025, 8:00 AM EDT - 1 year ago

iBio Reports Fiscal Third Quarter 2025 Financial Results

iBio, Inc. Quarterly report: Q3 2025

May 2, 2025, 8:00 AM EDT - 1 year ago

iBio, Inc. Quarterly report: Q3 2025

iBio, Inc. Earnings release: Q3 2025

May 2, 2025, 8:00 AM EDT - 1 year ago

iBio, Inc. Earnings release: Q3 2025

iBio Raises $6.2 Million Through Warrant Inducement Transaction

Apr 29, 2025, 1:43 PM EDT - 1 year ago

iBio Raises $6.2 Million Through Warrant Inducement Transaction

iBio Expands Cardiometabolic and Obesity Pipeline through Licensing of First-in-Class Antibody Targeting Activin E from AstralBio

Apr 22, 2025, 8:00 AM EDT - 1 year ago

iBio Expands Cardiometabolic and Obesity Pipeline through Licensing of First-in-Class Antibody Targeting Activin E from AstralBio

iBio Announces IBIO-600 Non-Human Primate Data Showing Extended Half-Life and Muscle Growth, and Interim In Vivo Results for First-in-Class Activin E Antibody, Advancing Cardiometabolic and Obesity Pipeline

Apr 7, 2025, 7:00 AM EDT - 1 year ago

iBio Announces IBIO-600 Non-Human Primate Data Showing Extended Half-Life and Muscle Growth, and Interim In Vivo Results for First-in-Class Activin E Antibody, Advancing Cardiometabolic and Obesity Pipeline

iBio to Begin Trading on the Nasdaq Stock Exchange

Feb 19, 2025, 4:05 PM EST - 1 year ago

iBio to Begin Trading on the Nasdaq Stock Exchange

iBio Reports Fiscal Second Quarter 2025 Financial Results

Feb 10, 2025, 4:05 PM EST - 1 year ago

iBio Reports Fiscal Second Quarter 2025 Financial Results

iBio, Inc. Quarterly report: Q2 2025

Feb 10, 2025, 4:00 PM EST - 1 year ago

iBio, Inc. Quarterly report: Q2 2025

iBio, Inc. Earnings release: Q2 2025

Feb 10, 2025, 4:00 PM EST - 1 year ago

iBio, Inc. Earnings release: Q2 2025

iBio, Inc. Registration statement: Registration Filing

Jan 31, 2025, 7:00 AM EST - 1 year ago

iBio, Inc. Registration statement: Registration Filing

iBio Expands Cardiometabolic and Obesity Program with Anti-Myostatin Antibody Discovered Using its Proprietary Platform, In-Licensed from AstralBio

Jan 2, 2025, 7:00 AM EST - 1 year ago

iBio Expands Cardiometabolic and Obesity Program with Anti-Myostatin Antibody Discovered Using its Proprietary Platform, In-Licensed from AstralBio

iBio Reports Fiscal First Quarter 2025 Financial Results

Nov 12, 2024, 4:05 PM EST - 1 year ago

iBio Reports Fiscal First Quarter 2025 Financial Results

iBio, Inc. Quarterly report: Q1 2025

Nov 12, 2024, 4:00 PM EST - 1 year ago

iBio, Inc. Quarterly report: Q1 2025

iBio, Inc. Earnings release: Q1 2025

Nov 12, 2024, 4:00 PM EST - 1 year ago

iBio, Inc. Earnings release: Q1 2025

iBio, Inc. Proxy statement: Proxy Filing

Oct 10, 2024, 8:00 AM EDT - 1 year ago

iBio, Inc. Proxy statement: Proxy Filing

iBio Reports Fiscal Year 2024 Financial Results and Provides Corporate Update

Sep 20, 2024, 4:05 PM EDT - 1 year ago

iBio Reports Fiscal Year 2024 Financial Results and Provides Corporate Update

iBio, Inc. Earnings release: Q4 2024

Sep 20, 2024, 4:00 PM EDT - 1 year ago

iBio, Inc. Earnings release: Q4 2024

iBio, Inc. Annual report: Q4 2024

Sep 20, 2024, 4:00 PM EDT - 1 year ago

iBio, Inc. Annual report: Q4 2024

iBio Expands Executive Leadership Team with Appointment of Kristi Sarno as Senior Vice President of Business Development

Aug 12, 2024, 4:30 PM EDT - 1 year ago

iBio Expands Executive Leadership Team with Appointment of Kristi Sarno as Senior Vice President of Business Development

iBio, Inc. Registration statement: Registration Filing

Jul 25, 2024, 8:00 AM EDT - 2 years ago

iBio, Inc. Registration statement: Registration Filing

iBio, Inc. Registration statement: Registration Filing

Jul 3, 2024, 8:00 AM EDT - 2 years ago

iBio, Inc. Registration statement: Registration Filing

iBio Closes Sale of Manufacturing Facility in Texas

Jun 3, 2024, 7:00 AM EDT - 2 years ago

iBio Closes Sale of Manufacturing Facility in Texas

iBio, Inc. Quarterly report: Q3 2024

May 14, 2024, 4:00 PM EDT - 2 years ago

iBio, Inc. Quarterly report: Q3 2024

iBio, Inc. Earnings release: Q3 2024

May 14, 2024, 4:00 PM EDT - 2 years ago

iBio, Inc. Earnings release: Q3 2024

iBio Reports Fiscal Third Quarter 2024 Financial Results and Provides Corporate Update

May 13, 2024, 4:05 PM EDT - 2 years ago

iBio Reports Fiscal Third Quarter 2024 Financial Results and Provides Corporate Update

iBio, Inc. Registration statement: Registration Filing

Apr 16, 2024, 8:00 AM EDT - 2 years ago

iBio, Inc. Registration statement: Registration Filing

iBio stock nearly tripled on Wednesday: here's why

Mar 27, 2024, 2:43 PM EDT - 2 years ago

iBio stock nearly tripled on Wednesday: here's why

iBio, Inc. Transcript: Collaboration

Mar 27, 2024, 8:30 AM EDT - 2 years ago

iBio, Inc. Transcript: Collaboration

iBio, Inc. Press release: Collaboration

Mar 27, 2024, 8:30 AM EDT - 2 years ago

iBio, Inc. Press release: Collaboration

iBio and AstralBio Announce Transformative AI drug discovery Collaboration to Rapidly Develop Novel Antibodies for Obesity and Cardiometabolic Diseases

Mar 27, 2024, 7:00 AM EDT - 2 years ago

iBio and AstralBio Announce Transformative AI drug discovery Collaboration to Rapidly Develop Novel Antibodies for Obesity and Cardiometabolic Diseases

iBio Announces $15.0 Million Private Placement

Mar 26, 2024, 7:35 PM EDT - 2 years ago

iBio Announces $15.0 Million Private Placement

iBio Announces Sale of Preclinical PD-1 Agonist Antibody Program to Otsuka

Feb 26, 2024, 7:45 AM EST - 2 years ago

iBio Announces Sale of Preclinical PD-1 Agonist Antibody Program to Otsuka

iBio, Inc. Quarterly report: Q2 2024

Feb 9, 2024, 4:00 PM EST - 2 years ago

iBio, Inc. Quarterly report: Q2 2024

iBio, Inc. Earnings release: Q2 2024

Feb 9, 2024, 4:00 PM EST - 2 years ago

iBio, Inc. Earnings release: Q2 2024

iBio Announces Participation in 23rd Annual PepTalk Conference

Jan 16, 2024, 8:15 AM EST - 2 years ago

iBio Announces Participation in 23rd Annual PepTalk Conference

iBio Amends and Extends Maturity of Credit Agreement

Dec 26, 2023, 7:15 AM EST - 2 years ago

iBio Amends and Extends Maturity of Credit Agreement

iBio, Inc. Announces Pricing of $4.5 Million Public Offering

Dec 5, 2023, 8:00 AM EST - 2 years ago

iBio, Inc. Announces Pricing of $4.5 Million Public Offering

iBio, Inc. Registration statement: Registration Filing

Nov 30, 2023, 7:00 AM EST - 2 years ago

iBio, Inc. Registration statement: Registration Filing

iBio Announces Reverse Stock Split

Nov 27, 2023, 5:20 PM EST - 2 years ago

iBio Announces Reverse Stock Split

iBio, Inc. Quarterly report: Q1 2024

Nov 14, 2023, 7:00 AM EST - 2 years ago

iBio, Inc. Quarterly report: Q1 2024

iBio, Inc. Earnings release: Q1 2024

Nov 14, 2023, 7:00 AM EST - 2 years ago

iBio, Inc. Earnings release: Q1 2024

iBio Further Expands Tech Stack with ShieldTx™; Enhances Immuno-Oncology Development Pipeline with Conditionally Activated MUC16xCD3 Bispecific

Nov 1, 2023, 8:24 AM EDT - 2 years ago

iBio Further Expands Tech Stack with ShieldTx™; Enhances Immuno-Oncology Development Pipeline with Conditionally Activated MUC16xCD3 Bispecific

iBio, Inc. Registration statement: Registration Filing

Oct 27, 2023, 8:00 AM EDT - 2 years ago

iBio, Inc. Registration statement: Registration Filing

iBio, Inc. Proxy statement: Proxy Filing

Oct 26, 2023, 8:00 AM EDT - 2 years ago

iBio, Inc. Proxy statement: Proxy Filing

iBio, Inc. Proxy statement: Proxy Filing

Oct 16, 2023, 8:00 AM EDT - 2 years ago

iBio, Inc. Proxy statement: Proxy Filing

iBio Explains Recent Filing of Registration Statement

Oct 2, 2023, 6:45 AM EDT - 2 years ago

iBio Explains Recent Filing of Registration Statement

iBio Announces Filing of 2023 Annual Report on SEC Form 10-K

Sep 27, 2023, 4:19 PM EDT - 2 years ago

iBio Announces Filing of 2023 Annual Report on SEC Form 10-K

iBio, Inc. Annual report: Q4 2023

Sep 27, 2023, 4:00 PM EDT - 2 years ago

iBio, Inc. Annual report: Q4 2023

iBio Announces Amendment to Credit Agreement with Woodforest

Sep 21, 2023, 4:05 PM EDT - 2 years ago

iBio Announces Amendment to Credit Agreement with Woodforest

iBio Reports Triple Milestone: In Vivo Proof-of-Concept for Three Programs, a Transformative Step in Advancing its Immuno-Oncology Pre-Clinical Pipeline Towards Clinical Development

Aug 14, 2023, 4:15 PM EDT - 3 years ago

iBio Reports Triple Milestone: In Vivo Proof-of-Concept for Three Programs, a Transformative Step in Advancing its Immuno-Oncology Pre-Clinical Pipeline Towards Clinical Development

iBio, Inc. Registration statement: Registration Filing

Aug 7, 2023, 8:00 AM EDT - 3 years ago

iBio, Inc. Registration statement: Registration Filing

iBio Appoints Dr. Martin Brenner as CEO, Felipe Duran as CFO to Oversee Company's Next Stage of Growth

Jun 27, 2023, 8:00 AM EDT - 3 years ago

iBio Appoints Dr. Martin Brenner as CEO, Felipe Duran as CFO to Oversee Company's Next Stage of Growth

iBio Forges Research Collaboration with the National Institutes of Health

Jun 12, 2023, 4:15 PM EDT - 3 years ago

iBio Forges Research Collaboration with the National Institutes of Health

iBio to Participate in the JMP Securities Life Sciences Conference

May 9, 2023, 4:30 PM EDT - 3 years ago

iBio to Participate in the JMP Securities Life Sciences Conference

Retail_Lives_Matter
Retail_Lives_Matter Jun. 4 at 6:59 PM
$IBIO
0 · Reply
Retail_Lives_Matter
Retail_Lives_Matter Jun. 4 at 3:03 AM
$IBIO so beautiful Marty….and yet your shareholders continue to eat 💩
2 · Reply
skitime
skitime Jun. 3 at 5:47 PM
$IBIO but what about the Ebola vaccine 🤷‍♂️
0 · Reply
focafoca99
focafoca99 Jun. 2 at 8:10 PM
$IBIO heads to the Jefferies Global Healthcare Conference on June 4 and the Leerink Partners Therapeutics Forum in July. https://www.rapidticker.com/news/ibio-ibio-to-participate-in-upcoming-0ec7fa
0 · Reply
Rower5oh
Rower5oh Jun. 2 at 8:10 PM
$IBIO “iBio is a clinical company now!!!” Price drops 7% 🤦‍♂️
1 · Reply
diagio
diagio Jun. 2 at 7:31 PM
$HUBC This idiot disappeared for 2 years when he lost his as on $IBIO he will disappear for another 2 years again. Look at his post history. 🤣
0 · Reply
Retail_Lives_Matter
Retail_Lives_Matter Jun. 2 at 6:40 PM
$IBIO remember when that POFS Tom said becoming a clinical stage company would be a major inflection point? I hope he stubs his toe really hard today.
1 · Reply
Bevobrack
Bevobrack Jun. 2 at 6:35 PM
$IBIO most news like this would warrant some interest and an uptick but not our IBIO lol. Wow. 😑
0 · Reply
Magglo
Magglo Jun. 2 at 6:27 PM
$IBIO ????
1 · Reply
Retail_Lives_Matter
Retail_Lives_Matter Jun. 2 at 12:22 PM
$IBIO
0 · Reply
focafoca99
focafoca99 Jun. 2 at 11:26 AM
$IBIO reports its first participant dosed in a Phase 1 trial, marking its transition to a clinical-stage biotech. https://www.rapidticker.com/news/ibio-ibio-becomes-a-clinical-stage-c4d62a
0 · Reply
leswa
leswa Jun. 1 at 4:06 AM
$IBIO this is literally .01 from a few years ago. What a scam.
0 · Reply
WZMAN7227
WZMAN7227 May. 31 at 5:20 PM
$IBIO You can track the trial's official postings and updates via the http://ClinicalTrials.gov identifier NCT07487376.
0 · Reply
WZMAN7227
WZMAN7227 May. 31 at 5:05 PM
$IBIO https://clinicaltrials.gov/study/NCT07487376
1 · Reply
SuperGreenToday
SuperGreenToday May. 30 at 2:43 AM
$IBIO
1 · Reply
Rower5oh
Rower5oh May. 28 at 6:43 PM
$IBIO
0 · Reply
Joelew22
Joelew22 May. 27 at 5:51 PM
$IBIO
0 · Reply
Retail_Lives_Matter
Retail_Lives_Matter May. 27 at 3:57 PM
$IBIO are we going to be waiting until this time next year for a (hopefully) successful P1 data read out? wtf is going to move the needle on this POFS? I digress…
1 · Reply
BIOCOIN
BIOCOIN May. 27 at 2:27 PM
$IBIO +2. target
1 · Reply
Rower5oh
Rower5oh May. 26 at 2:55 PM
$IBIO Tick tock, Martin.
1 · Reply
Joelew22
Joelew22 May. 22 at 3:26 PM
$IBIO took some profit in case, holding rest for better times, like this one this yr. Dip or rip good either way.
0 · Reply
CocaKolla
CocaKolla May. 22 at 4:44 AM
$IBIO 🥊✅
0 · Reply